Nitrofurantoin Versus Comparators in the Treatment of Cystitis due to Extended-Spectrum β-Lactamase–Producing Enterobacterales: A Multicenter Cohort Study
Annals of Pharmacotherapy · 2025
DOI: 10.1177/10600280251315950 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Abrar K Thabit und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Practice Department, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Cystitis, Nitrofurantoin, beta-Lactamases, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background
The increasing prevalence of extended-spectrum β-lactamase (ESBL)–producing bacteria has limited treatment options for cystitis. The recommendation of nitrofurantoin for treatment is based solely on in vitro studies.
Objective
We aimed to evaluate the effectiveness of nitrofurantoin versus comparators in treating cystitis due to ESBL-producing Enterobacterales in the clinical setting.
Methods
This was a multicenter retrospective cohort study of afebrile adults with symptomatic cystitis and a urine culture of ≥10 5 CFU/mL of ESBL-producing organism susceptible to nitrofurantoin and comparator antibiotics. Patients were categorized based on treatment (nitrofurantoin vs comparator). Clinical cure was the primary endpoint. Reinfection and relapse were secondary endpoints.
Results
Of 225 patients, 66 received nitrofurantoin and 159 received a comparator. Carbapenems were the most used comparator (57.2%). Clinical cure rates were not significantly different between the groups in crude (77.3% vs 86.2%; P = 0.101) and regression analyses (adjusted odds ratio [aOR], 0.82; 95% CI, 0.34-1.99). Of 35.4% of nitrofurantoin patients and 66.0% comparators group patients who had follow-up cultures, lower odds of relapse and reinfection were observed with nitrofurantoin, though not statistically significant (aOR, 0.28; 95% CI, 0.07-1.18 and aOR, 0.43 with 95% CI of 0.13-1.43, respectively). However, the inpatient setting was significantly associated with higher odds of relapse (aOR, 8.83; 95% CI, 1.07-72.74; P = 0.043). Conclusion and relevance: Nitrofurantoin was as effective as comparators in treating cystitis due to ESBL-producing Enterobacterales. The inpatient setting was associated with higher odds of relapse. Further larger research trials are needed to validate these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Practice Department, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
- Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
- College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
- King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
- Saudi Critical Care Pharmacy Research Platform, Riyadh, Saudi Arabia.
- Pharmacy Department, King Fahad Hospital, Jeddah, Saudi Arabia.
ORCID-Profile: Abrar K Thabit, Khalid Al Sulaiman, Khalid Eljaaly
Zitieren
APA
Thabit, A. K., Al Sulaiman, K., Alfaraj, L., Radwan, S. A., Almadfaa, L. O., Mokhtar, R. H., Alowais, S. A., Bin Saleh, K., Eljaaly, K., Alzahrani, A. A., Alshehri, A. J., Alofi, F. S., & Aljuhani, O. (2025). Nitrofurantoin Versus Comparators in the Treatment of Cystitis due to Extended-Spectrum β-Lactamase–Producing Enterobacterales: A Multicenter Cohort Study. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251315950
Vancouver
Thabit AK, Al Sulaiman K, Alfaraj L, Radwan SA, Almadfaa LO, Mokhtar RH, et al. Nitrofurantoin Versus Comparators in the Treatment of Cystitis due to Extended-Spectrum β-Lactamase–Producing Enterobacterales: A Multicenter Cohort Study. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280251315950
BibTeX
@article{Thabit2025,
author = {Thabit, Abrar K and Al Sulaiman, Khalid and Alfaraj, Lulwa and Radwan, Sarah A and Almadfaa, Layan O and Mokhtar, Raneen H and Alowais, Shuroug A and Bin Saleh, Khalid and Eljaaly, Khalid and Alzahrani, Abdulmajeed A and Alshehri, Abdulaziz J and Alofi, Fadwa S and Aljuhani, Ohoud},
title = {Nitrofurantoin Versus Comparators in the Treatment of Cystitis due to Extended-Spectrum β-Lactamase–Producing Enterobacterales: A Multicenter Cohort Study},
journal = {Annals of Pharmacotherapy},
year = {2025},
doi = {10.1177/10600280251315950}
}
EUVIMED